文献速递免疫规划卫生政策与健康促进

Ad.26.COV2.S疫苗上市后安全性监测:2021年2月至2022年2月向疫苗不良事件报告系统与v-safe的报告

Post-authorization safety surveillance of Ad.26.COV2.S vaccine: Reports to the Vaccine Adverse Event Reporting System and v-safe, February 2021-February 2022.
PubMed 文献 · Vaccine · 2023-06-14

分析2021年2月27日至2022年2月28日美国VAERS与v-safe数据,期间接种17,018,042剂Ad26.COV2.S,VAERS收到67,995份不良事件报告,多数为非严重。O/E分析显示18-64岁成人心肌心包炎报告率升高,接种后7天内RR为3.19(95%CI 2.00,4.83),21天内RR为1.79(95%CI 1.26,2.46)。结论确认TTS与GBS已知风险,并发现心肌炎的潜在安全信号。

要点

  • 17,018,042剂接种后VAERS收到67,995份报告,87.9%(59,750份)为非严重不良事件。
  • 18-64岁成人心肌心包炎O/E报告率比:接种后7天内RR 3.19(95%CI 2.00,4.83),21天内RR 1.79(95%CI 1.26,2.46)。
  • v-safe中60.9%报告局部症状、75.9%报告全身症状,33.9%报告健康影响,仅1.4%寻求医疗照护。

核心结论

  • 本次审查确认了TTS和GBS的已知安全风险,并发现心肌炎的潜在安全关切。

研究设计与样本

  • 对美国VAERS(被动监测系统)和v-safe(基于智能手机的监测系统)2021年2月27日至2022年2月28日的数据进行描述性分析。
  • 分析内容包括性别、年龄、种族/民族、严重性、特别关注不良事件(AESI)和死因。
  • 对预设AESI,使用Ad26.COV2.S总接种剂次计算报告率;对心肌心包炎,基于核实病例数、疫苗接种数据和已发表背景率进行观察值与预期值(O/E)分析。

主要发现

  • 分析期间美国共接种17,018,042剂Ad26.COV2.S,VAERS收到67,995份接种后不良事件报告。
  • 大多数不良事件(59,750份;87.9%)为非严重,与临床试验中观察到的相似。
  • 严重不良事件包括COVID-19疾病、凝血病(包括血栓形成伴血小板减少综合征,TTS)、心肌梗死、贝尔麻痹和吉兰-巴雷综合征(GBS)。
  • AESI报告率范围为每百万剂0.06(儿童多系统炎症综合征)至263.43(COVID-19疾病)。
  • O/E分析显示心肌心包炎报告率比升高:18-64岁成人接种后7天内RR为3.19(95%CI 2.00,4.83),21天内RR为1.79(95%CI 1.26,2.46)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: On 2/27/2021, FDA authorized Janssen COVID-19 Vaccine (Ad.26.COV2.S) for use in individuals 18 years of age and older. Vaccine safety was monitored using the Vaccine Adverse Event Reporting System (VAERS), a national passive surveillance system, and v-safe, a smartphone-based surveillance system. METHODS: VAERS and v-safe data from 2/27/2021 to 2/28/2022 were analyzed. Descriptive analyses included sex, age, race/ethnicity, seriousness, AEs of special interest (AESIs), and cause of death. For prespecified AESIs, reporting rates were calculated using the total number of doses of Ad26.COV2.S administered. For myopericarditis, observed-to-expected (O/E) analysis was performed based on the number verified cases, vaccine administration data, and published background rates. Proportions of v-safe participants reporting local and systemic reactions, as well as health impacts, were calculated. RESULTS: During the analytic period, 17,018,042 doses of Ad26.COV2.S were administered in the United States, and VAERS received 67,995 reports of AEs after Ad26.COV2.S vaccination. Most AEs (59,750; 87.9 %) were non-serious and were similar to those observed during clinical trials. Serious AEs included COVID-19 disease, coagulopathy (including thrombosis with thrombocytopenia syndrome; TTS), myocardial infarction, Bell's Palsy, and Guillain-Barré syndrome (GBS). Among AESIs, reporting rates per million doses of Ad26.COV2.S administered ranged from 0.06 for multisystem inflammatory syndrome in children to 263.43 for COVID-19 disease. O/E analysis revealed elevated reporting rate ratios (RRs) for myopericarditis; among adults ages 18-64 years, the RR was 3.19 (95 % CI 2.00, 4.83) within 7 days and 1.79 (95 % CI 1.26, 2.46) within 21 days of vaccination. Of 416,384 Ad26.COV2.S recipients enrolled into v-safe, 60.9 % reported local symptoms (e.g. injection site pain) and 75.9 % reported systemic symptoms (e.g., fatigue, headache). One-third of participants (141,334; 33.9 %) reported a health impact, but only 1.4 % sought medical care. CONCLUSION: Our review confirmed previously established safety risks for TTS and GBS and identified a potential safety concern for myocarditis.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Woo EJ, Gee J, Marquez P, et al. Post-authorization safety surveillance of Ad.26.COV2.S vaccine: Reports to the Vaccine Adverse Event Reporting System and v-safe, February 2021-February 2022. Vaccine. 2023. PMID: 37321898. doi:10.1016/j.vaccine.2023.06.023

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。